Pfizer's Chantix Warning May Remain As FDA Raises Trial Concerns
Executive Summary
FDA will present concerns on data collection and study conduct during advisory committee meeting on removing smoking cessation drug's boxed warning.
You may also be interested in...
Chantix's Boxed Warning: Will A Positive Vote Justify A Negative Outcome?
FDA could use advisory committee members' comments to maintain the smoking cessation drug's boxed warning, even though they voted to remove it.
Was FDA Nit-Picking In Criticism Of Pfizer's EAGLES Trial?
When industry rep questioned whether problems with smoking cession drug trial were overestimated, FDA's rebuke was swift.
Removing Pfizer's Chantix Boxed Warning A One-Off, Committee Says
Advisory committee says data supports dialing back safety label for the smoking cessation product, but shouldn’t be precedent setting.